Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).
The University of Maryland School of Medicine (UMSOM) is the joint recipient of $4.75 million in funding from the National Science Foundation to establish a new Center for Medical Innovations in Extended Reality.
Background: Although well recognized for its scientific value, data sharing from clinical trials remains limited. Steps toward harmonization and standardization are increasing in various pockets of the global scientific community. Th...
When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.
A stroke and subsequent brain injury qualified 65-year-old Linda Carmichael for a national, randomized clinical trial led locally by Sunil A. Sheth, MD, with McGovern Medical School at UTHealth Houston, investigating the safety and efficacy of endovascular thrombectomy plus medical management compared to medical management alone in certain LVO stroke patients.
A team of researchers from the National University of Singapore is pioneering a novel magnetic therapy as an effective companion therapy to chemotherapy for treatment of breast cancer. This therapy is localised, non-invasive and painless, and could improve the overall treatment outcome.
Ochsner Baton Rouge electrophysiologist Dr. Freddy Abi-Samra has successfully completed the region’s first heart pacemaker procedure in a clinical trial involving a new, breakthrough technology that could make pacemaker surgery available to patients who may not benefit from traditional technology.
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to The TOGETHER Trial: An Adaptive Platform International Trial.
Scientists have assessed the long-term effects of intranasal insulin on cognition and on gait in people with and without type 2 diabetes mellitus.
In hospitalized patients with COVID-19, the SGLT2 inhibitor dapagliflozin was well tolerated regardless of kidney function, but did not significantly lower patients’ risk of organ failure, kidney problems, or death compared with placebo.
Based upon a clinical trial of pregnant women at more than 70 sites, including Ochsner Health, doctors are recommending that even mild forms of high blood pressure be treated with medication.
CAR-T therapy, a form of immunotherapy that revs up T-cells to recognize and destroy cancer cells, has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and most recently, multiple myeloma. However, Black and Hispanic people were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration approval of CAR-T cell therapies.
Cardiologists and cardiothoracic surgeons from the Smidt Heart Institute at Cedars-Sinai are available to discuss the latest advances in research, clinical care, transcatheter procedures and cardiothoracic surgery throughout the International Society for Heart and Lung Transplantation (ISHLT) Scientific Sessions 2022 and Heart Rhythm 2022.
With the support of a $1.7 million grant from the National Institutes of Health, researchers at the School of Medicine will lead the Long-term Effectiveness of the Anti-Obesity medication Phentermine (LEAP) trial, a placebo-controlled, randomized-controlled trial that will enroll 1,000 adults at five sites across the U.S.
In a research letter to the journal JAMA Oncology, clinical researchers at Sylvester Comprehensive Cancer Center in the University of Miami Miller School of Medicine showed that immunotherapy can be an option for at least one subgroup of pancreatic cancer patients. The study found that patients with inherited BRCA and other similar mutations can achieve complete responses — in some cases going from near death to durable recoveries.
Bladder cancer affects nearly 84,000 people in the United States each year, making it the sixth most common cancer. Most people survive it, but unfortunately, many lose their bladders. Neda Hashemi, MD, and her team at The University of New Mexico Comprehensive Cancer Center are now offering several clinical trials, including one that will give people with bladder cancer a chance to fight their disease and keep their bladders.
The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently established the Sylvester Pancreatic Cancer Research Institute (SPCRI). The new center will support innovative research, increase collaborations between scientists and clinicians, and provide more treatment and clinical trial opportunities for patients.
Drug may safely boost platelet levels in patients with immune thrombocytopenia.
Rutgers researchers are calling for a change in our approach to developing COVID-19 vaccines, and vaccines to fight future pandemics, to incorporate both conventional and challenge trails.
Today, the U.S. Department of Energy (DOE) announced $1 million in funding for three awards to advance research and development (R&D) to translate newly developed radioisotopes into evaluation for potential use in preclinical and clinical trials. This funding is part of a key federal program that produces critical isotopes otherwise unavailable or in short supply for U.S. science, medicine, and industry.
The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program offers researchers a smoother path from basic science to clinical testing and regulatory approval.
Hackensack Meridian Hackensack University Medical Center started a new study investigating the impact of omega-3 supplements on post-COVID symptoms.
New data from MD Anderson-led studies on ATR inhibitor and next-generation PARP1 inhibitor presented at AACR Annual Meeting
New data to be presented by Grace Dy, MD, at the American Association for Cancer Research Annual Meeting show that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life.
Combining a beta-blocker with the cancer immunotherapy drug pembrolizumab could be a promising new treatment option for many hard-to-treat solid-tumor cancers. Researchers from Roswell Park Comprehensive Cancer Center will report on a study of of this treatment combination in patients with advanced or metastatic melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2022.
Two Roswell Park Comprehensive Cancer Center oncologists will discuss promising strategies for making breakthrough immunotherapies work for more patients at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana, on Monday, April 11.
Clinical trials are a pivotal tool for assessing the safety and efficacy of medical interventions, but sponsors often provide incomplete information for assessing their ethical justification.
UC San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.
Dozens of cancer specialists at Roswell Park Comprehensive Cancer Center have been invited to present their latest advances in cancer research at the annual meeting of the American Association for Cancer Research (AACR), which will take place in New Orleans, Louisiana, from April 8 to 13.
Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.
CEFALY Technology, a Belgium-based manufacturer of wearable medical devices for migraine, today announced the results of a clinical study demonstrating that two-hour treatment with the e-TNS CEFALY device is a safe and effective, non-pharmaceutical alternative for the acute treatment of migraine attacks in the out-of-hospital setting.
UCSF, in collaboration QLHC and the FDA, has developed the OneSource electronic data capture (EDC) system to seamlessly integrate clinical care and research by streamlining collection and distribution of patient health data for clinical trials. It is currently being deployed in the I-SPY COVID trial and expanding to I-SPY 2.2 trial for breast cancer.
Addressing disparities in cancer care, including access to and participation in clinical trials, has long been a priority for Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health. Sanjay Goel, MD, MS, director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute shares more.
A new drug shows promise in providing relief to hypertrophic cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.
Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental “gene silencing” therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%. Findings from the “APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial” were presented today during a late-breaking science session at American College of Cardiology’s 71st Annual Scientific Session and simultaneously published online in the Journal of the American Medical Association.
Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive genetic condition that causes movement challenges and cognitive decline. UC Davis MIND Institute researchers have shown, for the first time, how FXTAS can manifest in its earliest stages.
AU professor awarded $6.4 million grant for clinical trial researching dietary intervention in U.S. veterans suffering from Gulf War Illness
A comprehensive look at all of the active clinical trials on new CRISPR-based genome editing therapies in 2022, and perspective on what is coming next.
A study published in the Journal of the American Medical Association Surgery is the first in North America to demonstrate that living-donor liver transplant is a viable option for patients who have systemically controlled colorectal cancer and liver tumors that cannot be surgically removed.
Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But findings from a team at the University of Michigan Rogel Cancer Center, led by Carl Koschmann, M.D., pediatric neuro-oncologist at University of Michigan Health C.S. Mott Children’s Hospital and researcher with the Chad Carr Pediatric Brain Tumor Center, suggest a new method could provide additional data about tumor markers before changes appear on an MRI, indicating possible strategies to help clinicians address this aggressive form of cancer. The recent study appeared in Neuro-Oncology.
Background: The use of mobile health technologies has been necessary to deliver patient education to patients with diabetes during the COVID-19 pandemic. Objective: This open-label randomized controlled trial evaluat...
A team of clinical investigators at the Icahn School of Medicine at Mount Sinai has announced the launch of a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19.
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma (LBCL). The study was published today in Nature Medicine, and results recently were presented at the 2021 American Society of Hematology (ASH) meeting.
Letrozole and abemaciclib cause tumor shrinkage or stabilization in 75% of patients in phase 2 trial. Approximately 30% of trial participants had their tumors shrink by more than 30%
Now a couple of years after this discovery, Pete Nelson, the R.C. Durr Foundation Chair in Alzheimer's Disease at the University of Kentucky, is working towards the second part of the dream, with the world’s first clinical trial for LATE officially underway by his colleagues at UK.
UChicago researchers discovered several important mechanisms that affect how ovarian cancer tumors interact with the immune response and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
The Dementia Care Study (D-CARE), a nation-wide clinical trial assessing the effectiveness of different approaches to caring for people with Alzheimer’s disease and other dementias, has reached its recruitment goal by enrolling 2,176 persons living with dementia and their caregivers
The cost-effectiveness of interventions has attracted increasing interest among researchers.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
